Investment Rating - The report maintains a "Recommendation" rating for Dong'e Ejiao, with a target price of 72.5 yuan [2][8]. Core Insights - In Q1 2025, Dong'e Ejiao reported revenue of 1.72 billion yuan, representing an 18.2% year-over-year increase, and a net profit attributable to shareholders of 430 million yuan, up 20.2% year-over-year [2][4]. - The company emphasizes the resilience of its operations despite short-term cash flow fluctuations, with a focus on improving financial metrics such as cash flow and accounts receivable [2][8]. - The company is expected to achieve double-digit revenue growth in its Ejiao series due to channel expansion and increased online and offline sales activities [8]. Financial Performance Summary - Total revenue projections for Dong'e Ejiao are as follows: - 2024: 5.921 billion yuan - 2025: 6.919 billion yuan (16.9% growth) - 2026: 8.022 billion yuan (15.9% growth) - 2027: 9.191 billion yuan (14.6% growth) [4][9] - Net profit attributable to shareholders is projected to grow as follows: - 2024: 1.557 billion yuan - 2025: 1.869 billion yuan (20.0% growth) - 2026: 2.205 billion yuan (18.0% growth) - 2027: 2.602 billion yuan (18.0% growth) [4][9]. - The company maintains a low inventory level and a stable contract liability of 590 million yuan, indicating sufficient orders [8]. Strategic Focus - Dong'e Ejiao is committed to its "1238" strategy, aiming to expand its core Ejiao business and explore new growth areas such as male health products [8]. - The company has a high dividend payout ratio of 99.7% for 2024, indicating strong cash reserves and a commitment to shareholder returns [8]. - The management is focused on enhancing operational quality through comprehensive budget management and performance assessments [8].